Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy.

Department of Dermatology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan.
British Journal of Dermatology (Impact Factor: 3.76). 06/2004; 150(5):843-51. DOI: 10.1111/j.1365-2133.2004.05933.x
Source: PubMed

ABSTRACT The sera of epidermolysis bullosa acquisita (EBA) react with type VII collagen, a major component of anchoring fibrils, in which the major epitopes have been considered to be present in the N-terminal noncollagenous (NC) 1 domain.
To determine whether there are also epitopes in the C-terminal NC2 domain, and to determine their ultrastructural localization.
Immunoblotting using recombinant proteins of the NC1 and NC2 domains of type VII collagen, and postembedding immunoelectron microscopy.
Twenty of 28 EBA sera tested reacted with the NC1 domain and eight sera reacted with the NC2 domain. The sera that reacted with the NC1 domain showed immunoreactivity within the lamina densa and the sera that reacted with the NC2 domain showed immunoreactivity in the dermis 300-360 nm below the lamina densa.
This study clearly identified the presence of epitopes in the NC2 domain, and showed that the epitope in the NC1 domain is present in the lamina densa and that the epitope in the NC2 domain is in the dermis below the lamina densa.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen. Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished. Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal. However, with an emerging and more detailed understanding of the events ultimately leading to blister formation in EBA, novel therapeutic options may become available for patients with EBA. Therefore, this article reviews the current understanding of the pathogenesis of EBA and may indicate possible avenues towards a more targeted therapy for EBA and possibly other antibody-mediated autoimmune diseases.
    Dermatologic clinics 07/2011; 29(3):493-501, xi. · 1.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Type VII collagen (coll VII) ELISA has been reported to have high sensitivity (>93%) and specificity (>96%) for diagnosing epidermolysis bullosa acquisita (EBA) patients who are sero-positive by indirect immunofluorescence on salt-split skin (SSS). OBJECTIVES: To investigate the added value of coll VII ELISA in the laboratory diagnosis of SSS-positive and SSS-negative EBA and to correlate the ELISA index with disease episode. METHODS: Coll VII ELISA was performed on banked sera of 28 EBA patients: 15 SSS-positive and 13 SSS-negative. Sera from healthy blood donors (n=17) and other autoimmune blistering diseases (n=29) served as controls. In four patients ELISA index was measured longitudinally. Serration pattern analysis by DIF was prospectively performed since 2000 and comprised 19 patients. RESULTS: The sensitivity in the SSS-positive group was 80% whereas it was 23% in the SSS-negative group. In the prospective EBA subset it was 45%. The sensitivity of u-serration pattern analysis on skin biopsy was 89%. Ten (53%) of these cases were sero-negative by both ELISA and SSS, and would have been missed by serum analysis alone. Of the 46 control sera one serum tested positive (specificity 97.8%). The coll VII ELISA correlated with disease activity over time in individual patients. CONCLUSIONS: Coll VII ELISA has limited added value in SSS-negative EBA cases. The ELISA test is very valuable in differentiating EBA from anti-laminin-332 MMP and anti-p200 pemphigoid and in its ability to serological monitor EBA patients. U-serration pattern analysis on IF skin biopsy is the golden standard for the diagnosis of EBA.
    British Journal of Dermatology 03/2013; · 3.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidermolysis bullosa acquisita (EBA) is an autoimmune subepidermal blistering disease of mucous membranes and the skin caused by autoantibodies against collagen VII. In silico and wet laboratory epitope mapping studies revealed numerous distinct epitopes recognized by EBA patients' autoantibodies within the non-collagenous (NC)1 and NC2 domains of collagen VII. However, the distribution of pathogenic epitopes on collagen VII has not yet been described. In this study, we therefore performed an in vivo functional epitope mapping of pathogenic autoantibodies in experimental EBA. Animals (n = 10/group) immunized against fragments of the NC1 and NC2 domains of collagen VII or injected with antibodies generated against the same fragments developed to different extent experimental EBA. Our results demonstrate that antibodies targeting multiple, distinct epitopes distributed over the entire NC1, but not NC2 domain of collagen VII induce blistering skin disease in vivo. Our present findings have crucial implications for the development of antigen-specific B- and T cell-targeted therapies in EBA.
    Journal of Cellular and Molecular Medicine 08/2014; · 4.75 Impact Factor